/
AIM
$0.30-$0.02 (-5.09%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$8.7M
28M shares
52-week range
$0.21 – $20.33
0% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
XASE
CS
Borrow rate
160.35%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1.85
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $367.0K | $140.0K | $163.0K | $135.0K | $141.0K | $202.0K | $170.0K | $88.0K |
| Cost of revenue | $884.0K | $893.0K | $806.0K | $850.0K | $0 | $42.0K | $31.0K | $338.0K |
| Gross profit | −$517.0K | −$753.0K | −$643.0K | −$715.0K | $141.0K | $160.0K | $139.0K | −$250.0K |
| Gross margin | -140.9% | -537.9% | -394.5% | -529.6% | 100.0% | 79.2% | 81.8% | -284.1% |
| R&D | $4.8M | $4.7M | $5.7M | $7.7M | $7.0M | $10.9M | $6.2M | $3.9M |
| Operating income | −$11.5M | −$12.4M | −$15.2M | −$18.8M | −$19.9M | −$31.9M | −$19.8M | −$10.5M |
| EBITDA | −$8.4M | −$8.1M | −$13.0M | −$18.3M | −$19.2M | −$28.7M | −$16.5M | −$12.9M |
| Net income | −$9.8M | −$9.4M | −$14.4M | −$19.1M | −$19.4M | −$29.0M | −$17.3M | −$14.0M |
| Net margin | -2673.8% | -6717.1% | -8834.4% | -14168.1% | -13790.8% | -14337.6% | -10188.2% | -15861.4% |
| EPS (diluted) | -355.19 | -93.71 | -16.41 | -14.67 | -14.69 | -21.64 | -11.22 | -8.62 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $61000 | $-0.90 | $-1.07–$-0.73 | 1 |
| 2027 | $100000 | $-0.70 | $-0.84–$-0.57 | 1 |
| 2028 | $51M | $-0.73 | $-0.87–$-0.59 | 1 |
| 2029 | $74454 | $-0.60 | $-0.72–$-0.48 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
www.aimimmuno.com- Employees
- 21
- IPO / List date
- Nov 2, 1995
- HQ
- OCALA, FL
Held by traders on TradeandTell
No one on the platform currently holds AIM.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in AIM as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-09 | 1001-for-1000 |
| 2019-06-11 | 1-for-44reverse |
| 2016-08-29 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded AIM yet.
